Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-07-10. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0001628280-26-047909
acquired disposedA
codeM
direct or indirectD
form4
is derivativefalse
issuer nameContineum Therapeutics, Inc.
labelExercise of derivative
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0001628280-26-047909",
"acquired_disposed": "A",
"code": "M",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "Contineum Therapeutics, Inc.",
"label": "Exercise of derivative",
"person_name": "Lorrain Daniel S.",
"price": 1.01,
"role": "Chief Scientific Officer",
"security": "Class A Common Stock",
"shares": 25,
"shares_owned_after": 135227,
"source_path": "edgar/data/1855175/0001628280-26-047909.txt",
"ticker": "CTNM",
"value": 25.25
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.